New Milestones in Drug Development – Blog Post by Asrar Qureshi
Dear Colleagues! This is Pharma Veterans Blog Post #218. Pharma Veterans shares the wealth of knowledge and wisdom of Veterans for the benefit of Pharma Community. Pharma Veterans Blog is published by Asrar Qureshi on WordPress , the top blog site. If you wish to share your stories, ideas and thoughts, please email to asrar@asrarqureshi.com for publishing your contributions here . New Gene Therapy for SMA – ZOLGENSMA by Novartis FDA approved 59 NMEs (New Molecular Entities) in 2018 and 12 up to now in 2019. 2 , 3 . A review of these approvals sheds light on what is happening in the Drug Development Scene. Drug Development has changed in several ways in recent times. It is mostly going away from mainstream indications and towards specific ‘unmet needs’, rare diseases, orphan drugs, new classes such as Nibs (small molecule kinase inhibitors), Nabs (nanoparticle, Albumin based), Mibs (proteasome inhibitors), mAbs (monoclonal Antibodies based) and so on. The bot...